免疫检查点抑制剂（ICB）革命性地改变了肿瘤治疗，但超过半数患者面临原发性耐药，其中 EGFR 突变型非小细胞肺癌（NSCLC）是典型代表。携带 EGFR 激活突变的患者对 ICB 响应极差，这导致占肺癌人群近半的患者在靶向治疗失败后陷入无药可用的困境。尽管已知这类肿瘤多呈「冷肿瘤」特征（低免疫浸润、低突变负荷），但 EGFR ...

引言表皮生长因子受体（EGFR）突变是非小细胞肺癌（NSCLC）的重要驱动因素，EGFR 酪氨酸激酶抑制剂（TKI）已成为其标准一线治疗。然而，患者在接受 TKI 治疗后普遍出现获得性耐药，导致疾病进展，后续治疗选择有限且疗效欠佳。铂类化疗作为患者 EGFR TKI 治疗进展后的主要手段，中位无进展生存期（PFS）仅 2.8-4.9 ...

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...

近年来，针对罕见靶点突变阳性NSCLC的治疗策略持续取得重要突破，呈现药物选择不断丰富的可喜局面。其中部分靶向疗法已获批应用于临床，更多药物则正处于临床试验阶段，并在多项国际前沿研究中显示出令人鼓舞的疗效信号，为患者带来了新的生存希望。

Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and ...

WILMINGTON, Del.--(BUSINESS WIRE)--Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or ...